Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.38 |
| ▸ | WNT3A | P56704 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29815997 | 1.00 | ERCC5 (0.43) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL27864902 | 0.82 | PTPN1 (0.43) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL27864912 | 0.80 | CTSC (0.33) | — | |
| SCHEMBL29815743 | 0.80 | ERCC5 (0.49) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL193821 | 0.80 | ERCC5 (0.49) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL194430 | 0.78 | TSHR (0.49) | ERCC5FEN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL194599 | 0.78 | PTPN1 (0.39) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL194294 | 0.76 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1156376 | 0.72 | MEN1 (0.47) | ERCC5FEN1CTNNB1WNT3AKMT2A | |
| SCHEMBL1156101 | 0.72 | ERCC5 (0.45) | ERCC5FEN1CTNNB1WNT3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | TAKEDA PHARMACEUTICALS CO (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3241826-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2765130-B1 | Intermediates for use in a process of producing pyrrole compounds | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-2402313-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2765130-A2 | Process for producing pyrrole compound | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | ERCC5 4793/4885FEN1 3744/4885CTNNB1 4504/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | CYP3A5, CYP3A4, CBR3 | ERCC5 4566/4885FEN1 3612/4885CTNNB1 4373/4885 |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-10844011-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | ERCC5 4616/4885FEN1 2724/4885CTNNB1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.